Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.66 |
| ▸ | TXN | P10599 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MASP2 | O00187 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846351 | 1.00 | NPSR1 (0.66) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL229852 | 0.89 | NPSR1 (0.68) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL13049405 | 0.84 | NPSR1 (0.72) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL38661952 | 0.84 | NPSR1 (0.61) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL6755353 | 0.84 | NPSR1 (0.61) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL19866370 | 0.84 | NPSR1 (0.61) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL15294544 | 0.84 | NPSR1 (0.61) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL13073559 | 0.81 | NPSR1 (0.58) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL19540740 | 0.81 | NPSR1 (0.58) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL20283848 | 0.81 | NPSR1 (0.58) | NPSR1TXNHDAC6ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260150576-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2026-05-28 | — | — | US | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4172164-B1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2025-08-27 | — | — | EP | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | NPSR1 3573/4885TXN 1514/4885HDAC6 1315/4885 |
| US-20260150576-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | ESRRA, NR3C1, NR2C2 | NPSR1 273/4885TXN 1023/4885HDAC6 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.